超重与肥胖人群抗反流手术的围术期并发症与中期结局
该回顾性队列研究纳入338例BMI≥25 kg/m²并接受初次微创抗反流手术的患者,按BMI分层比较围术期并发症、疝复发、生活质量和满意度。结果显示III度肥胖组术中并发症和ICU入住率显著更高,而BMI 25-40 kg/m²组生活质量改善明显且满意度高。
要点
- III度肥胖(BMI≥40)患者术中并发症和ICU入住率显著高于其他BMI组。
- BMI 25-40 kg/m²患者术后GERD-HRQL评分改善且满意度高。
- II度肥胖患者在减重手术受限时可考虑直接行抗反流手术。
核心结论
- 微创抗反流手术对超重和非病态肥胖患者安全性良好,可控制反流并改善生活质量。
- 当减重手术受限时,II度肥胖患者可考虑直接行抗反流手术。
研究设计与样本
- 回顾性队列研究,纳入2016年9月至2025年6月由经验丰富的食管外科医生行初次择期微创抗反流手术的连续患者。
- 共338例BMI≥25 kg/m²患者,按BMI分层:超重25-30(n=172)、I度肥胖30-35(n=125)、II度肥胖35-40(n=30)、III度肥胖≥40(n=11)。
- 排除既往食管手术或非胃底折叠抗反流手术(如磁性括约肌增强)者。
主要发现
- 术中并发症率在超重、I度、II度、III度肥胖组分别为3.5%、4.8%、3.3%、27.3%(p=0.006)。
- ICU入住率分别为1.7%、4%、3.3%、18.2%(p<0.026)。
- 早期术后并发症率分别为7.6%、8.8%、6.7%、27.3%(p=0.153)。
- 客观食管裂孔疝复发(>2 cm)仅见于1例超重和2例I度肥胖患者,II度/III度肥胖组无复发。
- BMI 25-40 kg/m²组GERD-HRQL评分改善且患者满意度高。
关键数值与推荐
- 术中并发症和ICU入住率在III度肥胖组显著升高(p=0.006和p<0.026)。
- 早期术后并发症在III度肥胖组略高但差异无统计学意义(p=0.153)。
- 随访≥12个月的患者比例分别为55.2%、51.2%、50%、27.3%,中位随访时间24-36个月。
临床怎么用
- 对BMI 25-40 kg/m²患者,微创抗反流手术可提供良好的反流控制和生活质量改善。
- 对III度肥胖患者,需充分评估围术期风险,术中并发症和ICU入住率较高。
- II度肥胖患者在减重手术受限时可考虑直接行抗反流手术。
局限性
- 回顾性研究设计。
- III度肥胖组样本量小(n=11)。
- 随访率在III度肥胖组较低(27.3%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As the worldwide prevalence of obesity increases, more patients with obesity are referred for antireflux surgery (ARS). Although bariatric surgery is typically recommended, at times straightforward ARS is offered. We aimed to compare surgical and patient-reported outcomes among overweight and obese patients undergoing minimally invasive ARS. METHODS: This retrospective cohort study included consecutive patients with BMI ≥ 25 kg/m2 who underwent primary elective ARS by an experienced foregut surgeon (September 2016-June 2025). Patients were stratified by BMI: overweight 25-30, class I obesity 30-35, class II obesity 35-40, and class III obesity ≥ 40 kg/m2. Exclusions included prior foregut procedures or non-fundoplication ARS (e.g., magnetic sphincter augmentation). Outcomes of interest were perioperative morbidity, hernia recurrence, midterm quality-of-life scores, and patient satisfaction. RESULTS: A total of 338 patients (71.6% female; median age: 65.1 [54.6-73.1] years) were stratified into the BMI groups: overweight (n = 172, 50.9%), class I (n = 125, 36.9%), class II (n = 30, 8.9%), and class III (n = 11, 3.3%). Intraoperative complication rates (3.5, 4.8, 3.3, and 27.3%; p = 0.006) and ICU admission rates (1.7, 4, 3.3, and 18.2%; p < 0.026) were significantly higher, and early postoperative complications were slightly higher (7.6, 8.8, 6.7, and 27.3%; p = 0.153) in the class III obesity group. Follow-up ≥ 12 months was available for 95/172 (55.2%), 64/125 (51.2%), 15/30 (50%), and 3/11 (27.3%) patients per group with similar median durations (24-36 months). Objective hiatal hernia recurrence (> 2 cm) was observed in 1 overweight and 2 class-I patients, but no class-II/III patients. Improved quality-of-life (GERD-HRQL) scores and high patient satisfaction, especially in the 25-40 kg/m2 BMI groups, were reported. CONCLUSION: Minimally invasive ARS provides a favorable safety profile along with gastroesophageal reflux control and improved quality of life for overweight and non-morbidly obese patients. Particularly, straightforward ARS for patients with class II obesity may be considered when limitations on bariatric surgery exist.
引用
- Latorre-Rodríguez AR, Vittori A, Takeuchi H, et al. Perioperative morbidity and midterm outcomes following antireflux surgery in overweight and obese populations. Surg Endosc. 2026. PMID: 42563044. doi:10.1007/s00464-026-13263-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。